[{"id":"a7e65987-5f6c-4e7e-a85e-bdb565899b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05901519","created_at":"2023-06-13T17:08:04.132Z","updated_at":"2024-07-02T16:35:15.919Z","phase":"Phase 2","brief_title":"A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma","source_id_and_acronym":"NCT05901519","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" TNFRSF1A","pipe":"","alterations":" ","tags":["TNFRSF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-07"},{"id":"06ab7f9b-1285-4ff7-8e07-6a4608ecb3c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922035","created_at":"2024-02-22T20:26:04.668Z","updated_at":"2024-07-02T16:35:18.238Z","phase":"Phase 1","brief_title":"CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant","source_id_and_acronym":"NCT03922035","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFA • TNFRSF1A • TGFB1","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/24/2024","study_completion_date":" 12/24/2024","last_update_posted":"2024-02-22"},{"id":"c684a821-6f24-49f9-8bae-75d401eba5f5","acronym":"M-Tech","url":"https://clinicaltrials.gov/study/NCT05153447","created_at":"2024-01-09T17:19:21.538Z","updated_at":"2024-07-02T16:35:24.090Z","phase":"","brief_title":"A Multicomponent Technology Supported Care Delivery for Older Patients With Hematologic Malignancies (The M-Tech Study)","source_id_and_acronym":"NCT05153447 - M-Tech","lead_sponsor":"Kah Poh Loh","biomarkers":" IL6 • TNFA • IL2 • IL10 • TNFRSF1A • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • IL10 • TNFRSF1A • IL1B"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-09"},{"id":"8e2d1c4a-7b49-4dea-9f5e-49901e61a123","acronym":"","url":"https://clinicaltrials.gov/study/NCT02849717","created_at":"2021-01-18T13:59:21.944Z","updated_at":"2024-07-02T16:35:47.943Z","phase":"","brief_title":"Pre-Habilitation Exercise Intervention","source_id_and_acronym":"NCT02849717","lead_sponsor":"University of Rochester","biomarkers":" IL6 • IL10 • TNFRSF1A • IL1B","pipe":"","alterations":" ","tags":["IL6 • IL10 • TNFRSF1A • IL1B"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2023-05-16"},{"id":"9a28d489-9909-417b-b32a-2274c2c36b22","acronym":"PRO-YOU","url":"https://clinicaltrials.gov/study/NCT02489422","created_at":"2021-01-18T11:59:59.431Z","updated_at":"2024-07-02T16:36:02.462Z","phase":"","brief_title":"Programs To Support You During Chemotherapy","source_id_and_acronym":"NCT02489422 - PRO-YOU","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" IL6 • TNFA • TNFRSF1A","pipe":"","alterations":" ","tags":["IL6 • TNFA • TNFRSF1A"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-10-14"},{"id":"9d5d5843-6c1a-4962-9944-d62b1100d273","acronym":"CP7-005","url":"https://clinicaltrials.gov/study/NCT04004910","created_at":"2021-01-18T19:40:50.808Z","updated_at":"2024-07-02T16:36:14.782Z","phase":"Phase 1/2","brief_title":"A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients","source_id_and_acronym":"NCT04004910 - CP7-005","lead_sponsor":"Immunicom Inc","biomarkers":" TNFA • TNFRSF1A","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2022-03-24"},{"id":"4c34974e-7f53-4129-b9b2-21fab6af69b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04690686","created_at":"2021-01-19T20:48:33.871Z","updated_at":"2024-07-02T16:36:15.881Z","phase":"Phase 2","brief_title":"Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).","source_id_and_acronym":"NCT04690686","lead_sponsor":"Immunicom Inc","biomarkers":" EGFR • ALK • ROS1 • TNFA • TNFRSF1A","pipe":" | ","alterations":" ALK fusion • ROS1 fusion","tags":["EGFR • ALK • ROS1 • TNFA • TNFRSF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-03-08"},{"id":"05e4868a-8c2e-478b-9391-b195c4a9d451","acronym":"","url":"https://clinicaltrials.gov/study/NCT04142931","created_at":"2021-01-18T20:13:20.965Z","updated_at":"2024-07-02T16:36:32.898Z","phase":"Phase 1","brief_title":"Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors","source_id_and_acronym":"NCT04142931","lead_sponsor":"Dr. Ronnie Shapira","biomarkers":" TNFA • TNFRSF1A","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/24/2020","start_date":" 02/24/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-03-24"},{"id":"1d125168-4730-4672-881f-6ff02bbf726d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02421978","created_at":"2021-01-18T11:34:59.030Z","updated_at":"2024-07-02T16:36:57.453Z","phase":"","brief_title":"Inflammation-Induced CNS Glutamate During Breast Cancer Treatment","source_id_and_acronym":"NCT02421978","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • TNFRSF1A • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • TNFRSF1A • CRP"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 05/29/2018","study_completion_date":" 05/29/2018","last_update_posted":"2019-08-01"},{"id":"686a1d8f-18f0-46ad-8ca2-03150889547f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01833884","created_at":"2021-01-18T08:09:46.527Z","updated_at":"2024-07-02T16:37:19.687Z","phase":"","brief_title":"Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic","source_id_and_acronym":"NCT01833884","lead_sponsor":"Centre Henri Becquerel","biomarkers":" IL6 • TNFRSF1A • IL1R1","pipe":"","alterations":" ","tags":["IL6 • TNFRSF1A • IL1R1"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-07-21"},{"id":"c7cb12bd-00a5-4666-8ffc-015f0ac907fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093623","created_at":"2021-01-18T15:14:29.764Z","updated_at":"2024-07-02T16:37:23.535Z","phase":"","brief_title":"The Effect of Physical Activity and Abstain From Smoking on the Precancerous Lesion","source_id_and_acronym":"NCT03093623","lead_sponsor":"Taipei Medical University","biomarkers":" IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5","pipe":"","alterations":" ","tags":["IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5"],"overall_status":"Unknown status","enrollment":" Enrollment 446","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-04-11"}]